Medical therapy of XXXX .

@entity2657 @entity3126 @entity3791 @entity26 @entity619 @entity5754 @entity221
@entity5754 ( @entity5754 ) and @entity3126 ( @entity3126 ) continue to cause significant morbidity and occasional deaths among mountain recreationists and residents. Descent to lower altitude is still considered the treatment of choice, but an increased role for medical therapy is emerging. @entity3791 is currently the drug of choice for prevention of @entity5754 , and probably @entity3126 as well. Numerous studies have demonstrated the drug's effectiveness when it is started 12 to 24 hours before ascent. Suggestions for indications, dosage, and regimen vary with different authors. Lower dosage offers adequate protection with fewer side effects. @entity3791 has still not been adequately studied for treatment of @entity221 . @entity26 effectively treats @entity3126 and mild @entity5754 , but is not as useful for @entity2657 . @entity619 recently was found effective for treatment of @entity5754 , including early @entity2657 , but not for advanced @entity2657 . Side effects limit its use for prophylaxis, but @entity619 offers an alternative to @entity3791 for those with sulfa intolerance.
